Mutation Profile Detection, Therapeutic Resistance and Clonal Evolution Assessed With Liquid Biopsy of Advanced NSCLC Patients in China
Sponsor study identifier
observational
300
1 country
14
Study Start
February 22, 2017
Actual (reported)Primary Completion
December 31, 2019
Actual (reported)Study Completion
January 30, 2020
Actual (reported)To evaluate the concordance of sensitizing mutations detected between paired plasma and tissue samples; the correlation between the clonal status of sensitizing mutations and targeted therapy response; and the prognostic impact of the relative abundance of sensitizing / resistance mutations.
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
January 30, 2020
Actual (reported)Click on a node to explore related trials.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
February 16, 2017
Actual (reported)February 22, 2017
Actual (reported)February 23, 2017
Actual (reported)December 31, 2019
Actual (reported)January 30, 2020
Actual (reported)The mutation pattern of untreated advanced NSCLC and evolution of ctDNA mutation profile during TKI treatment.
2 years
The concordance of gene mutation pattern between liquid biopsy and tissue biopsy.
1 year
treatment naïve Stage IIIB or Stage IV NSCLC patients, adenocarcinoma or squamous cell carcinoma without smoking history
The First Affiliated Hospital of Guangzhou Medical University
Guangzhou, Guangdong, 510120, China
First Hospital of Jilin University
Changchun, China
Sir Run Run Shaw Hospital, Zhejiang University School of medicine
Hangzhou, China
The First Hospital of Zhejiang Province
Hangzhou, China
Anhui Provincial Hospital
Hefei, China
Jiangsu Jiangyin People's Hospital
Jiangyin, China
The Second Affiliated Hospital of Nanchang University
Nanchang, China
Ai X, Cui J, Zhang J, Chen R, Lin W, Xie C, Liu A, Zhang J, Yang W, Hu X, Hu X, Zhao Q, Rao C, Zang YS, Ning R, Li P, Chang L, Yi X, Lu S. Clonal Architecture of EGFR Mutation Predicts the Efficacy of EGFR-Tyrosine Kinase Inhibitors in Advanced NSCLC: A Prospective Multicenter Study (NCT03059641). Clin Cancer Res. 2021 Feb 1;27(3):704-712. doi: 10.1158/1078-0432.CCR-20-3063. Epub 2020 Nov 13.
whole blood (including plasma, white cells), tissue
Shun Lu, MD
Shanghai Chest Hospital
300 participants (actual enrollment reported by the registry).
First Submitted
February 16, 2017
First Posted
February 23, 2017
Study Start
February 22, 2017
Actual (reported)Effect of Pulmonary Rehabilitation on Perioperative Outcomes in Smoker Patients With Lung Cancer
Contact the study team to confirm eligibility.
Ningbo No.2 Hospital
Ningbo, China
Ruijin Hospital, Shanghai Jiaotong University School of Medicine
Shanghai, China
Shanghai Changzheng Hospital
Shanghai, China
Shanghai Chest Hospital
Shanghai, China
Shanghai East Hospital
Shanghai, China
The First Affiliated Hospital of Wenzhou Medical University
Wenzhou, China
Affiliated Hospital, Jiangnan University
Wuxi, China
Primary Completion
December 31, 2019
Actual (reported)Study Completion
January 30, 2020
Actual (reported)Last Updated
February 5, 2020
Record last verified: 2020-02
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: